Bora Pharmaceuticals announced that its shareholders' meeting approved the waiver of non-competition restrictions for directors. Directors such as Sheng Bao-Xi and their representatives will be permitted to engage in business activities similar to the company's scope of business during their tenure. This resolution complies with Article 209 of the Company Act and is not expected to have a significant impact on the company's financial or business operations.
1. Date of Shareholders' Meeting Resolution: 115/06/09
2. Names and Titles of Directors Permitted to Engage in Competitive Business:
Director: Sheng Bao-Xi
Director: Bora International Co., Ltd. and its representative Chen Guan-Bai
Director: Wang Jin-Ju
Independent Director: Li Yi-Qin
Independent Director: Lai Ming-Rong
Independent Director: Lin Xin-Yi
Independent Director: Qiu Qi-Hua
3. Scope of Permitted Competitive Business: Items similar to the company's business scope
4. Duration of Permitted Competitive Business: During the term of office as a director of the company
5. Resolution Details (Explain the voting result in accordance with Article 209 of the Company Act): In accordance with the provisions of Article 209 of the Company Act, after voting at the company's ordinary shareholders' meeting on 115/06/09, the resolution to waive the non-competition restrictions for the above-mentioned directors was approved as proposed.
6. Names and Titles of Directors if the Permitted Competitive Business is with a Mainland China Enterprise (If not with a Mainland China Enterprise, please enter "Not Applicable"): Not Applicable
7. Company Name and Position in the Mainland China Enterprise: Not Applicable
8. Address of the Mainland China Enterprise: Not Applicable
9. Business Items of the Mainland China Enterprise: Not Applicable
10. Impact on the Company's Financial and Business Operations: Not Applicable
11. If Directors Invest in Mainland China Enterprises, Investment Amount and Shareholding Ratio: Not Applicable
12. Other Matters to be Noted: None
FACT BOX
- Source: PR Times
- Category: Corporate Governance
- Dates in source: 115/06/09
FAQ
What was the main resolution approved at Bora Pharmaceuticals' shareholders' meeting?
The shareholders' meeting approved the waiver of non-competition restrictions for certain directors, allowing them to engage in activities similar to the company's business scope during their tenure.
Which directors have had their non-competition restrictions waived?
This includes Mr. Sheng Bao-Xi, the representative of Bora International Co., Ltd., Ms. Wang Jin-Ju, and four independent directors: Ms. Li Yi-Qin, Mr. Lai Ming-Rong, Ms. Lin Xin-Yi, and Mr. Qiu Qi-Hua.
What is the expected impact of this resolution on the company's business?
According to the announcement, the impact on the company's financial and business operations is deemed 'Not Applicable,' suggesting no significant impact is anticipated.
What does the waiver of non-competition restrictions signify for the company's future?
By allowing directors to engage in a broader range of business activities, it may lead to the creation of new business opportunities and the strengthening of existing operations.
How does this decision relate to the company's corporate governance?
This represents an adjustment in the company's governance structure, interpreted as an effort to maximize directors' expertise and enhance corporate value.